APP and Alzheimer disease: Therefore, by SDS-PAGE Western blotting with specific antibodies (AT8/Tau-1 6E10), we further analyzed the soluble ocular homogenates from mouse retina and vitreous bodies to evaluate whether the treatment with 12A12mAb could impact on the AD-like tau hyperphosphorylation and APP/Aβ misprocessing/accumulation.